Max Cotler joined GelMEDIX before during its founding as a consultant in 2020 and has stayed with the company in increasing roles now as Chief Operating Officer. Prior to GelMEDIX, Max completed his PhD in Medical Engineering and Medical Physics at the Massachusetts Institute of Technology in the Harvard-MIT Program in Health Sciences and Technology (HST). His research focused on drug delivery device development at the micron scale in neurology and oncology. Max also holds a BS in biomedical engineering from Boston University.